Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia

Trial Profile

A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vixotrigine (Primary)
  • Indications Trigeminal neuralgia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Biogen
  • Most Recent Events

    • 13 Dec 2018 Planned End Date changed from 13 Feb 2023 to 7 Aug 2023.
    • 13 Dec 2018 Planned primary completion date changed from 15 Feb 2021 to 9 Aug 2022.
    • 13 Dec 2018 Planned initiation date changed from 29 Nov 2018 to 31 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top